Mass Photometry sheds light on the binding mechanism of the bispecific tetravalent anti-VEGF-PD-1 antibody Ivonescimab

Ivonescimab is a next-generation bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), two key molecules in the tumour microenvironment. It's dual mechanism suggests enhanced therapeutic potential. Ivonescimab binding to VEGF dimers can potentially lead to interconnection or daisy chaining of multiple ivonescimab molecules, which may lead to increased binding of T cells.

 

However, details of nature of theses complexes, precise stoichiometry, affinities, complex formation dynamics between ivonescimab and its targets, have remained poorly characterized due to limitations of existing analytical techniques.

 

In this webinar, we will show how we used mass photometry, a single molecule imaging technique capable of detecting biomolecular complexes in solution, to characterize ivonescimab’s binding behaviour with VEGF and PD-1.

 

We will show how real-time analysis enables observation of complex formation throughout the incubation period and quantification of the stability and prevalence of each complex. We will also show that we can calculate dissociation constant for each complex in the equilibrium as well as examples showcasing how crucial it is to do QC of antigens, for correct interpretation of complex dynamics.

 

Join me to discover how mass photometry can advance design of the next generation of therapeutic bispecific antibodies, with rapid and quantitative insight into dynamic, complex, and multi-target antigen interactions.

 

 

 

Mass photometry can advance bispecific antibody development by: